Clinical trials: No Condition
Colon Cancer
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
In this research study, investigators use colonoscopy as a case example to evaluate a predictive overbooking model derived using patient-level predictors of absenteeism.
- Trial name
- No-show (NCT01639443)
- Testing
- Predictive no-show overbooking
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Infection
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora.
- Trial name
- PREVENT2 (NCT04815876)
- Testing
- Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
- Where
- 16 sites in United States
- Volunteers
- 1,040 people
- Sponsor
- Weill Medical College of Cornell University
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00656448
- Testing
- Procrit
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- ABC (NCT00479674)
- Testing
- Abraxane, Bevacizumab, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Multiple Myeloma
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with…
- Trial name
- EVOLUTION (NCT00507442)
- Testing
- VELCADE (bortezomib), dexamethasone, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gynecology
An Endometrial Cancer Chemoprevention Study of Metformin
The goal of this clinical research study is to learn about the effects of metformin and/or a program called "lifestyle intervention" on the endometrium (inner lining of the uterus) in post-menopausal women who are also obese…
- Trial name
- NCT01697566
- Testing
- Metformin, Endometrial Biopsy, Lifestyle Intervention
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Secondary Lung Cancer
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study
This is a Phase 3 study aimed at investigating the effects of a personalized exercise program (PEP) in NSCLC patients (stage I, II, IIIa) and secondary lung cancer patients undergoing surgical treatment at the University of Utah…
- Trial name
- PEP (NCT03306992)
- Testing
- Personalized Exercise Program
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of Utah
Polycythemia Vera
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (PV) who were hydroxyurea…
- Trial name
- NCT02292446
- Testing
- Ruxolitinib
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 161 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee, Pain
A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control
This is a multi-center, randomized, double-blind clinical trial to examine the comparative effects on OAKP of CGS-200-1 (1% Capsaicin content) (N=40), CGS-200-5 (5% Capsaicin content) (N=40), and CGS-200 Vehicle (no Capsaicin)…
- Trial name
- NCT03528369
- Testing
- CGS-200-1, CGS-200-5, CGS-200 Vehicle
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Propella Therapeutics
TBI, Anxiety
Cranial Electrotherapy Stimulation (CES) Therapy
The primary aim of this proposed study is to gather preliminary data for CES use in treating PTSD and anxiety symptoms in OEF/OIF Veterans with PTSD and a history of TBI.
- Conditions
- TBI, Anxiety, PTSD, Depression
- Trial name
- CES (NCT02453347)
- Testing
- CES Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Covid19
Enriched Heparin Anti COVID-19 Trial
Coronavirus 19 (COVID-19) is a viral respiratory disease that was identified in December 2019 after the first cases in China, spreading rapidly until reaching pandemic status, causing the collapse of numerous health systems and…
- Trial name
- EnHanCed (NCT04743011)
- Testing
- Heparin sodium
- Where
- 2 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Assessment of the Precision of the Sherlock 3CG Tip Positioning System
Phase I determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude Phase II determine the precision of PICC placement in the Sherlock 3CG group versus the standard…
- Trial name
- STAT-PICC (NCT01275430)
- Testing
- Sherlock 3CG, Blind Placement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- C. R. Bard
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Generalized Pustular Psoriasis
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no…
- Trial name
- NCT05200247
- Testing
- spesolimab
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
Respiratory Failure
Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE
Insertion of a breathing tube to enable treatment with mechanical ventilation (respirator) is often associated with complications, such as infection and lung injury.
- Trial name
- NO-ASPIRATE (NCT02284178)
- Testing
- Enhanced oropharyngeal suction, Usual Care
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- University of Central Florida
Hepatocellular Carcinoma (HCC)
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
- Trial name
- NCT00355238
- Testing
- brivanib (active)
- Where
- 37 sites in United States, France and 6 more
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer